Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 18/20 | 0.57 |
| ▸ | THRA | P10827 | 8/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22632750 | 1.00 | THRB (0.57) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL29414838 | 0.89 | THRB (0.42) | THRBTHRA | |
| SCHEMBL22632721 | 0.87 | THRB (0.60) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL23663170 | 0.85 | THRB (0.65) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL22632658 | 0.84 | THRB (0.59) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL22632655 | 0.84 | THRB (0.59) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL23663470 | 0.81 | THRB (0.60) | THRBTHRA | |
| SCHEMBL29414683 | 0.81 | THRA (0.51) | THRBTHRA | |
| SCHEMBL22632525 | 0.81 | THRA (0.51) | THRBTHRA | |
| SCHEMBL31258413 | 0.79 | THRA (0.41) | THRBTHRAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304561-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4523692-A2 | MODULATORS OF THR-SS AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-3965884-B1 | MODULATORS OF THR-BETA WITH A DIOXO-1,2,4-TRIAZYL HEAD GROUP | ALIGOS THERAPEUTICS INC (US) | 2025-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304561-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | THRB, THRA, TRHR | THRB 1/4885THRA 2/4885CYP2C9 3117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.